Empagliflozin (Jardiance®). HTA ID: 21030
Empagliflozin (Jardiance®) is indicated for the treatment of symptomatic chronic heart failure with reduced ejection fraction.
| NCPE Assessment Process | Complete |
| Rapid review commissioned | 05/07/2021 |
| Rapid review completed | 29/07/2021 |
| Rapid Review outcome | A full HTA is recommended to assess the clinical effectiveness and cost effectiveness of empagliflozin compared with the current standard of care. |
| Full pharmacoeconomic assessment commissioned by HSE | 24/08/2021 |
| Pre-submission consultation with Applicant | 18/10/2021 |
| Full submission received from Applicant | 12/01/2022 |
| Preliminary Review sent to Applicant | 28/02/2022 |
| NCPE assessment re-commenced | 28/03/2022 |
| Factual Accuracy Check sent to Applicant | 30/03/2022 |
| NCPE assessment re-commenced | 07/04/2022 |
| NCPE assessment completed | 28/04/2022 |
| NCPE assessment outcome |
The NCPE considers empagliflozin to be a cost-effective treatment for adults with symptomatic chronic heart failure with reduced ejection fraction and reimbursement is recommended*. |
*This recommendation should be considered while also having regard to the criteria specified in the Health (Pricing and Supply of Medical Goods) Act 2013.